Lansing, MI-based Niowave has signed a supply agreement with Ratio Therapeutics to provide current good manufacturing practice (cGMP) Actinium-225 (Ac-225) to support Ratio's targeted radiotherapeutics pipeline.
Under the agreement, Niowave will supply the alpha-emitting radioisotope to support ongoing clinical trial activities and future program advancement, the companies said.
